Is Retatrutide FDA-Approved? Not Yet. Here's Where It Stands

No. As of October 22, 2026, retatrutide is an investigational drug with no FDA approval for any use: Eli Lilly has reported phase 3 results from its TRIUMPH program and has said it plans to submit the drug to the FDA in the first quarter of 2027. Approval status can change, so check the FDA's Drugs@FDA database or Lilly's announcements for the current position.

Until then, the only lawful routes to the investigational drug are Lilly's clinical trials and its limited early-access pathway. Products sold online under the name are not that drug.

What retatrutide is

Retatrutide, coded LY3437943 in its early trials, is a single molecule that activates three hormone receptors: those for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon, as described in the phase 2 and phase 3 publications. The two approved drugs most often compared with it act on fewer: semaglutide on the GLP-1 receptor, and tirzepatide on the GLP-1 and GIP receptors. Our review of the incretin class covers how those receptors fit together.

What the trials showed

All of the figures below are means from company-sponsored trials, reported for the trial's highest treatment arm against placebo. They describe trial populations under trial conditions, not what any individual would experience.

Phase 2 (Jastreboff and colleagues, New England Journal of Medicine, 2023). 338 adults with obesity, or overweight with a weight-related condition, were randomized to retatrutide or placebo for 48 weeks. At 48 weeks the mean change in body weight in the top arm was a reduction of 24.2%, against 2.1% on placebo. Gastrointestinal events were the most common adverse events and were more frequent in the higher arms, and heart rate rose, peaking at 24 weeks and declining after that.

TRIUMPH-1 (Jastreboff and colleagues, New England Journal of Medicine, published online September 29, 2026). This phase 3 trial randomized 2,339 adults with obesity and without diabetes for 80 weeks. In the intention-to-treat analysis, mean weight fell 25.0% in the top arm against 3.9% on placebo. Subgroups also showed reduced knee pain scores in 574 participants with knee osteoarthritis and fewer breathing interruptions per hour in 243 participants with obstructive sleep apnea. The most common adverse events were gastrointestinal. Lilly's May 2026 topline release reported larger weight figures from a different analysis of the same trial; the peer-reviewed numbers are the ones quoted here.

TRIUMPH-2 and TRIUMPH-3 (Lilly topline results, July 2026). TRIUMPH-2 enrolled 1,152 adults with type 2 diabetes and obesity or overweight, with a mean weight reduction of 20.8% in the top arm against 4.0% on placebo at 80 weeks. TRIUMPH-3 enrolled 1,949 adults with a body mass index of 35 or higher and established cardiovascular disease, with a reduction of 22.6% against 3.2%. BioPharma Dive reported that the most common side effects were diarrhea, nausea, constipation and vomiting, and that TRIUMPH-3 was not designed to show cardiovascular benefit. These two have not been peer-reviewed in full.

None of these trials compared retatrutide directly with an approved drug, so differences from semaglutide or tirzepatide trial results are indicative, not head-to-head findings. Our news report on the TRIUMPH readouts covers the tolerability data in more detail.

Where approval stands

Lilly has said it will file in the first quarter of 2027. According to BioPharma Dive, the company told CNBC it needed more time to gather manufacturing and quality-control data. A filing would start an FDA review, which is not a decision. We found no FDA filing, advisory meeting or approval for retatrutide as of this writing.

In August 2026 Lilly confirmed a limited pathway for some patients to request the drug before approval, through a treating physician. AJMC reported that published accounts of the eligibility criteria differed and that some obesity physicians wanted more safety data before using it outside a monitored trial. That pathway is run by the manufacturer. It is not an approval and does not extend to anyone else's product.

Why research-market material is not the investigational drug

The trial results above belong to Lilly's product: a specific molecule, made under controls the company documents to regulators, studied under a protocol, with adverse events tracked. A vial sold online with the same name is a different product. It has none of that documentation, and its contents depend entirely on the seller. Even an accurate certificate of analysis can show only what is in that lot, not that the trial findings apply to it. Our guide to reading a certificate covers what a certificate can and cannot establish.

Compounding is not a route either. In a March 31, 2025 letter shared with state pharmacy boards by the National Association of Boards of Pharmacy, the FDA said retatrutide has no USP monograph, is not a component of an approved drug, and is not on the 503A bulks list or the 503B bulks list, so compounded retatrutide does not qualify for the compounding exemptions. The agency's GLP-1 page, current as of October 1, 2026, states that retatrutide cannot be used in compounding under federal law.

Enforcement context

The FDA's GLP-1 page says the agency has warned companies that sold unapproved drugs containing retatrutide and other GLP-1 drugs labeled "for research purposes" or "not for human consumption" directly to consumers, and has also warned telehealth companies, ingredient distributors and outsourcing facilities over retatrutide. On August 24, 2026 it sent warning letters to online peptide sellers; one cited a product listed as "GLP-3R" and identified as retatrutide among the unapproved new drugs it found. That letter treated research-style wording on the site, such as "under investigation for its potential effects," as part of the evidence of intended human use. Our coverage of those letters and our explainer on research use only go further.

In sport, retatrutide is not named on the World Anti-Doping Agency's 2026 Prohibited List, but section S0 covers substances with no current government approval for human use and expressly includes drugs in clinical development. Athletes should check with their anti-doping organization.

Frequently asked questions

Is retatrutide FDA-approved?

No. It is investigational. Lilly plans to submit it to the FDA in the first quarter of 2027, and an FDA decision would follow a review after that.

When will retatrutide be approved?

No date exists. Lilly has given a filing target, not an approval date, and FDA reviews can end in approval, a request for more data, or rejection.

Can a pharmacy compound retatrutide?

No. The FDA says retatrutide does not qualify for compounding under either section 503A or 503B.

Is "research" retatrutide sold online the same as Lilly's drug?

No. It is a different product with none of the trial program's manufacturing or safety record, and the FDA has issued warning letters to sellers of it.

Sources:

Retatrutide is not FDA-approved. Nothing here is medical advice, dosing guidance or a treatment claim. Research use only.

For research use only · Not for human or veterinary use · No research compound discussed here is FDA-approved for any indication